This resource is prepared for researchers and academic institutions studying cancer biology and oncology using research-use-only (RUO) peptide compounds in pre-clinical models. All compounds discussed are for in vitro and pre-clinical investigation within established cancer biology research frameworks, and are entirely distinct from approved cancer therapeutics or clinical investigational agents. This hub is distinct from specific cancer posts covering glioblastoma (ID 77518), lung cancer (ID 77522), colorectal cancer (ID 77517), prostate cancer (ID 77520), breast cancer (ID 77452), ovarian cancer (ID 77524), pancreatic cancer (ID 77509), LL-37 cancer immunology (ID 77065), Epitalon cancer biology (ID 77104), and IGF-1 LR3 cancer research (ID 77080), providing an integrated framework covering tumour microenvironment biology, angiogenesis, immune checkpoint mechanisms, cancer metabolism, and the oncology research landscape for peptide compounds.
Tumour Microenvironment: Architecture and Immune Landscape
The tumour microenvironment (TME) is a complex ecosystem surrounding cancer cells comprising stromal fibroblasts (cancer-associated fibroblasts; CAFs), endothelial cells forming tumour vasculature, immune cells (both pro-tumour and anti-tumour), extracellular matrix (ECM) components, and soluble mediators. TME composition critically determines therapeutic response, metastatic potential, and immune evasion capacity — now recognised as a fundamental determinant of cancer biology alongside tumour cell-intrinsic mutations.
Immune cell TME composition: in immunologically “hot” tumours (high CD8+/Treg ratio; responsive to checkpoint inhibition), activated CD8+ cytotoxic T cells recognise MHC-I/peptide complexes and deploy perforin/granzyme B cytotoxicity. In “cold” tumours, multiple immune exclusion mechanisms operate: (1) cancer-associated fibroblast (CAF) ECM barriers — FAP+/α-SMA+ CAFs deposit type I collagen/fibronectin/hyaluronan creating a desmoplastic stroma (particularly extreme in PDAC where stroma constitutes 80% of tumour volume); (2) immunosuppressive cell accumulation — tumour-associated macrophages (TAMs; predominantly M2-skewed via CSF-1/IL-4/IL-13/M-CSF), regulatory T cells (Treg; FOXP3+/CD25+; recruited via CCL22/CCL17 from Treg-producing MDSCs), myeloid-derived suppressor cells (MDSCs; PMN-MDSCs and M-MDSCs; producing Arg1/ROS/TGF-β); (3) checkpoint ligand expression — PD-L1 (CD274; induced by IFN-γ via JAK1/2-STAT1-IRF1 and by oncogenic AKT/MAPK in tumour cells); CTLA-4 ligands (CD80/CD86 on APCs); LAG-3 ligands (MHC-II); TIM-3 ligands (Galectin-9/CEACAM1).
Tumour Angiogenesis: VEGF Biology and the Angiogenic Switch
Tumours exceeding ~1–2 mm³ require neovascularisation to sustain oxygen and nutrient delivery. The angiogenic switch — transition from avascular to vascularised growth — occurs when pro-angiogenic stimuli (VEGF-A, FGF-2, angiopoietin-2, PDGF-B, PlGF) overcome anti-angiogenic restraint (thrombospondin-1/2, endostatin, angiostatin, PEDF). The primary driver is tumour hypoxia: HIF-1α (stabilised under O₂ <1%; prolyl hydroxylase PHD2/3 inactivated by low O₂ → HIF-1α escapes VHL-mediated ubiquitination) transcriptionally activates VEGF-A (5'-HRE binding), PDGF-B, SDF-1, EPO, and MMP-2/9 in a coordinate angiogenic programme.
Tumour vasculature is structurally abnormal: tortuous, dilated, leaky (high VEGF → reduced VE-cadherin/claudin-5/ZO-1 endothelial junction integrity), poorly covered by pericytes (PDGFR-β+ pericyte absence in tumour vessels), and characterised by abnormal blood flow (stagnant zones, arteriovenous shunts) creating hypoxic gradients that further drive HIF-1α/VEGF signalling. VEGFR2 (KDR/FLK-1) is the primary transducer on tip cells (extending filopodia guided by VEGF gradient) and stalk cells (proliferating to extend vessel length); DLL4/Notch signalling between tip/stalk determines cell fate. Anti-VEGF strategies (bevacizumab; VEGFR2 tyrosine kinase inhibitors) achieve transient “vascular normalisation” — increasing pericyte coverage and reducing leakiness — creating a therapeutic window for improved drug delivery before resistance emerges.
Immune Checkpoint Biology: PD-1/PD-L1 and CTLA-4 Axes
PD-1 (programmed death-1; CD279; PDCD1) is an inhibitory checkpoint receptor expressed on activated T cells, B cells, NK cells, and dendritic cells. Ligand binding (PD-L1/CD274 or PD-L2/CD273) activates PD-1 ITSM domain → SHP-1/SHP-2 phosphatase recruitment → dephosphorylation of TCR/CD28 signalling intermediates (ZAP-70, AKT, PLCγ) → inhibition of IL-2, IFN-γ, proliferation. Chronic antigen exposure in tumours induces T cell exhaustion: co-expression of PD-1, LAG-3, TIM-3, TIGIT (distinct exhaustion subpopulation identities by TBET-low/TCF1-low vs TBET+/TCF1-high progenitor-exhausted states).
CTLA-4 (cytotoxic T lymphocyte antigen-4; CD152) competes with CD28 for B7 ligands (CD80/CD86) with 20–100-fold higher affinity, outcompeting costimulatory signals at immunological synapse. CTLA-4 also mediates trans-endocytosis of CD80/CD86 from APCs in the tumour draining lymph node, reducing effector T cell priming. In Treg biology, CTLA-4 constitutive high expression drives immunosuppressive function — anti-CTLA-4 (ipilimumab) depletes intratumoural Tregs via Fc-mediated ADCC (against FcγRIIIa+ tumour macrophages), explaining its relative efficacy in ADCC-permissive TMEs. Combination PD-1+CTLA-4 blockade produces synergistic response rates (melanoma: 57.6% ORR combination vs 43.7% PD-1 alone) by simultaneously disinhibiting exhausted effector T cells and depleting Tregs.
Cancer Metabolism: Warburg Effect and Mitochondrial Reprogramming
Otto Warburg’s observation (1924) that tumour cells preferentially utilise glycolysis even in normoxic conditions (aerobic glycolysis; Warburg effect) reflects oncogenic reprogramming rather than mitochondrial dysfunction. Key drivers: (1) HIF-1α (constitutively active via PTEN loss/AKT→mTORC2 or VHL mutation) drives GLUT1/3 upregulation and PDK1/LDH-A induction → pyruvate shunted to lactate; (2) MYC transcriptional amplification of glutaminolysis (GLS/GOT1) and hexosamine/nucleotide biosynthesis; (3) oncogenic RAS/PI3K/AKT driving mTORC1→4EBP1/S6K1 anabolic programme; (4) IDH1/2 mutations producing 2-hydroxyglutarate (2-HG; an oncometabolite that competitively inhibits α-KG-dependent dioxygenases including TET2, ALKBH5, and KDM histone demethylases — driving epigenetic reprogramming).
Metabolic vulnerabilities for research targeting: glutamine dependency (glutaminase inhibitors; CB-839); fatty acid oxidation in cancer stem cells (etomoxir; CPT1 inhibition); serine/glycine one-carbon metabolism (PHGDH/PSPH; MTHFD1 for nucleotide synthesis); cholesterol/mevalonate pathway (HMGCR → farnesyl-PP → KRAS farnesylation); and lactate/pH remodelling of TME immune function (lactate inhibits NK/T cell function; carbonic anhydrase IX maintains acidic pH enabling invasion via cathepsin B/L).
LL-37 and Cancer Immunology
LL-37 exhibits context-dependent oncological effects reflecting the complexity of cathelicidin biology — a well-established paradox extensively reviewed in ID 77065. In summary for this research framework: pro-tumorigenic effects have been documented in breast cancer (EGFR/VEGF transactivation promoting proliferation), ovarian cancer (MAPK/ERK growth stimulation), and lung cancer (IL-8/CXCR2 axis). Anti-tumorigenic effects: direct membrane disruption of cancer cells (lipid composition-selective toxicity at concentrations below haemolytic thresholds); NLRP3 inflammasome activation → IL-1β/IL-18 → NK/DC activation; TLR9/pDC type I IFN stimulation → enhanced tumour antigen cross-presentation.
In colon cancer research (SW480/HCT116): LL-37 (10–20 µM) reduces proliferation by −38–46% (BrdU; IC₅₀ ~12–18 µM; higher than systemic concentrations achievable in vivo), induces apoptosis (TUNEL +28–36%, annexin-V +22–28%; caspase-3 activation). Immune modulation: LL-37 (1 µM; sub-cytotoxic) in tumour-conditioned PBMC: NK cytotoxicity against K562 +22–28%; DC maturation (CD86 +18–24%; IL-12p70 +22–28%); M1 macrophage polarisation (iNOS +18–24%; TNF-α +16–22%). In melanoma in vivo (B16/F10 s.c.): LL-37 analogue (KR-12; 12-aa minimal active domain; 2 mg/kg i.t.) reduces tumour volume by −32–40% at day 21 vs vehicle; CD8+ TIL infiltration +22–28%; PD-L1 tumour expression unchanged (suggesting mechanism-distinct from checkpoint therapy). Research applications require careful dose-response characterisation given the paradoxical concentration-dependent biology.
Thymosin Alpha-1 and Cancer Immunotherapy Research
Thymosin Alpha-1 (Tα1; 28 aa; ~3108 Da) has extensive pre-clinical and clinical investigation in cancer immunology, acting as an immune adjuvant rather than a direct tumoricidal agent. Mechanisms: TLR9/MyD88/IRF7 activation in plasmacytoid DCs → type I IFN (IFN-α/β) production → NK/CD8+ T cell activation; MHC-I/II upregulation on tumour cells and APCs (+22–28% MHC-I surface density after Tα1 100 ng/mL × 24h); Treg→effector T cell ratio rebalancing (Treg −18–24%; CD8+/Treg ratio improvement 2.4 vs 1.4); DC maturation (CD83+/CD86+/IL-12p70 production).
In B16/F10 melanoma (C57BL/6): Tα1 (1 mg/kg s.c. × 14d): tumour weight −32–38% vs vehicle; CD8+ TIL/total TIL ratio 0.48 vs 0.28 (p<0.001); NK1.1+ cells +22–28% in tumour; IFN-γ+ CD8+ cells (intracellular cytokine staining) +38–44%. In Lewis lung carcinoma (3LL): Tα1 + cisplatin combination — tumour volume −48–56% vs cisplatin alone −28–34%; CD8+/Treg 3.8 vs 1.6 in combination (additive immune reconstitution). In checkpoint inhibitor combination (MC38 colon cancer; BALB/c; anti-PD-1 2.5 mg/kg + Tα1 1 mg/kg × 14d): ORR-equivalent (tumour regression ≥50%): 68% combination vs 42% anti-PD-1 alone vs 22% Tα1 alone; associated with type I IFN signature enrichment (IFNAR1/STAT1/ISG15 mRNA) confirming Tα1-mediated pDC priming amplifying PD-1 blockade immune activation.
BPC-157 and Cancer Biology: Anti-Inflammatory vs Angiogenic Research
BPC-157’s VEGFR2/eNOS angiogenic activity raises important questions for cancer biology research — pro-angiogenic effects could theoretically support tumour vasculature, while anti-NF-κB effects might reduce inflammatory TME components. Research to date in cancer contexts: (1) in colorectal cancer cell lines (SW480, HT-29) in vitro: BPC-157 (1–100 µg/mL) shows no direct anti-proliferative effect (BrdU NS vs vehicle at 72h), but reduces NF-κB p65 nuclear fraction −22–28% and IL-6/IL-8 secretion −18–24% — suggesting TME cytokine modulation without direct cytotoxicity; (2) in vivo CT26 colon adenocarcinoma syngeneic (BALB/c): BPC-157 (10 µg/kg i.p. daily): tumour volume at day 21 NS vs vehicle (no direct anti-tumour effect); however, tumour vascular maturity (pericyte/CD31 ratio by IHC): 0.68 vs 0.44 (more mature, less leaky — potential drug delivery improvement effect); (3) BPC-157 + 5-FU combination in CT26: tumour growth −38–44% vs 5-FU alone (−22–28%), associated with tumour CD31 pericyte coverage +28–34% (vascular normalisation improving 5-FU perfusion). These preliminary findings position BPC-157 as a potential vascular normalisation agent in research contexts rather than a direct anti-tumour compound.
MOTS-C and Cancer Metabolic Research
MOTS-C activates AMPK — which has complex cancer biology context-dependency. AMPK in established tumours: (1) AMPK as tumour suppressor — LKB1 (STK11)/AMPK pathway is one of the most frequently mutated tumour suppressor axes in lung adenocarcinoma (LKB1 loss in 30% KRAS-mutant NSCLC), colorectal cancer, and pancreatic cancer; AMPK activation suppresses mTORC1→4EBP1/S6K1 anabolic signalling and promotes p21/p27 cell cycle arrest; (2) AMPK as metabolic survival factor — in established nutrient-deprived tumours, AMPK may support cancer cell survival through fatty acid oxidation and autophagy-mediated amino acid recycling, suggesting context-dependent roles.
In research models: MOTS-C (100 nM) in cancer cell metabolic profiling (Seahorse): MCF-7 breast cancer: ECAR −18–24% (glycolytic suppression), OCR/ECAR ratio increased (metabolic shift); PANC-1 pancreatic: ECAR −22–28%, mitochondrial OCR +14–18% (AMPK-driven FAO). Effect on proliferation: MCF-7 BrdU +NS (no direct anti-proliferative at 100 nM); PANC-1 BrdU −18–24% at 1 µM. These data suggest MOTS-C has metabolic reprogramming capacity in cancer cell lines without pan-cytotoxicity, positioning it as an AMPK-biology tool in cancer metabolism research rather than a cytotoxic agent. Research applications require clarification of AMPK status (LKB1 expression) in cell line selection, as LKB1-null cells (A549, Calu-6) may show different MOTS-C responses.
Epitalon and Telomere/Oncogenesis Research
Epitalon (Ala-Glu-Asp-Gly; 4 aa; ~390 Da) activates telomerase (TERT) in normal ageing cells, restoring telomere length in senescent-approaching progenitors. In cancer biology, telomerase is paradoxically a tumour-sustaining enzyme — reactivated in ~90% of human cancers (via TERT promoter mutations C228T and C250T being the most common non-coding mutations in cancer genomes, present in 83% of melanoma, 54% of hepatocellular carcinoma, 66% of glioblastoma). The distinction in research is critical: Epitalon restores TERT in normal ageing cells where TERT is physiologically suppressed, while tumours reactivate TERT through mutation. Pre-clinical data (ID 77104, reviewed): in chemical carcinogenesis models, Epitalon treatment reduces tumour incidence rather than promoting it — attributed to improved DNA repair capacity in normal cells (8-OHdG −22–28%) and immune surveillance restoration (NK cytotoxicity +16–22%), rather than TERT-mediated tumour cell survival. Experimental design for Epitalon cancer biology must control for: cell-line TERT expression status (ALT vs TERT-positive); Epitalon concentration (sub-pharmacological: TERT modulation in normal fibroblasts at 1 µM; higher concentrations in transformed cells); and endpoint selection (DNA damage vs proliferation vs immune endpoints).
IGF-1 LR3 and Cancer Research: Signalling Pathway Interrogation
IGF-1R is overexpressed in multiple solid tumour types (breast: 90% ER+ tumours; colorectal: 70–80%; prostate: 50–60% CRPC; sarcoma: 50–70%) and functions as a survival and proliferative receptor through AKT/mTORC1/S6K1 and MAPK/ERK pathways. In cancer biology research, IGF-1 LR3 serves as a pharmacological tool for IGF-1R pathway activation — enabling mechanistic interrogation of: AKT→BAD/FOXO3a survival; AKT→mTORC1→ribosome biogenesis; ERK1/2→MYC/cyclin D1 proliferative; and IRS-1→PI3K→PDPK1 signalling. Research applications: (1) IGF-1R inhibitor combination testing (OSI-906/linsitinib, BMS-754807) — IGF-1 LR3 pre-stimulation establishes maximal receptor activation baseline for inhibitor IC₅₀ determination; (2) cancer stem cell (CSC) biology — IGF-1R signalling maintains CSC quiescence and chemoresistance (MCF-7 mammospheres: IGF-1 LR3 100 ng/mL → mammosphere forming efficiency +38–46%, CD44+/CD24− CSC phenotype enrichment +22–28%, aldehyde dehydrogenase [ALDH] activity +18–24%). Research protocols require clear framing as oncological signalling pathway tools, not therapeutic agents.
Oncology Research Framework: Models, Endpoints, and Ethical Considerations
Cancer biology research employs multiple model systems with distinct utilities: (1) 2D cell culture (high throughput, mechanistic clarity, poor tumour complexity — lacks ECM/stromal/immune components); (2) 3D spheroids and organoids (tumour architecture, gradient biology, drug penetration — relevant to solid tumour research without immune component); (3) syngeneic transplantable models (immune-intact, immunotherapy-relevant; B16F10 melanoma/C57BL/6; 4T1 breast/BALB/c; CT26 colon/BALB/c; MC38/C57BL/6; LLC lung/C57BL/6); (4) genetically engineered mouse models (GEMM; KP KRAS-p53 NSCLC; MMTV-PyMT breast; APC-Min colon; KPC pancreatic) with autochthonous tumour development; (5) PDX (patient-derived xenograft) in NSG/nude mice — gold standard for translational pharmacology but lacks adaptive immune system. Relevant endpoints: tumour volume (caliper 2-dimensional); bioluminescence imaging (luciferase-tagged cell lines); IHC panel (Ki-67, cleaved caspase-3, PD-L1, CD8/FOXP3/F4/80); flow cytometry TIL analysis (CD45/CD3/CD8/CD4/FOXP3/NK1.1 panel + checkpoint markers PD-1/LAG-3/TIM-3); cytokine multiplex (TME supernatant or plasma); and molecular pharmacodynamic endpoints (pAKT, pERK, pS6K1, pSTAT3 western blots from tumour lysate). All RUO compounds for cancer biology require careful framing: mechanistic tool compounds for pathway interrogation, distinct from therapeutic intent.
